TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31268011
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy
Study: 29695208
Drug: Antagonist protocol
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist protocol (group C)
Study: 22349668
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) oral drops
Study: 22349668
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral drops
Study: 19703572
Drug: Xenon (glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon (glutamate receptor antagonist)
Study: 16151341
Drug: 16-channel sequential
Normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-channel sequential stimulation with 2500 pps per channel
Study: 16151341
Drug: 8-channel sequential
Normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-channel sequential stimulation with 5000 pps per channel
Study: 8533058
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (vigabatrin, lamotrigine, gabapentin, oxcarbazepine, felbamate)
Study: 902005
Drug: Tablet identification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet identification card
Study: 30845333
Drug: Vi-polysaccharide conjugate
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-polysaccharide conjugate vaccine (Vi-TCV)
Study: 23593139
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at acupoint (treatment group)
Study: 21768545
Drug: Insulin-sensitizing strategy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-sensitizing strategy
Study: 20110037
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of bicalutamide 50-mg tablets
Study: 11718031
Drug: Mifepristone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 5 mg (Group A)
Study: 11718031
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg (Group B)
Study: 2574626
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg) twice daily
Study: 31143019
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of chronic sinusitis
Study: 24623024
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IT)
Study: 12882067
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of metoclopramide
Study: 7734367
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cladribine/m2/d
Study: 7398190
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg/70 kg body weight (intravenously or orally)
Study: 6342648
Drug: Topical PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PUVA with 2-h interval therapy (1% 8-methoxypsoralen followed by UV-A exposure 2 hours later)
Study: 6342648
Drug: Topical PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PUVA with non-interval therapy (1% 8-methoxypsoralen followed by UV-A exposure within 5 minutes)
Study: 30630792
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of tranexamic acid and glutathione
Study: 7859936
Drug: Low-dose bedtime
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bedtime insulin alone
Study: 25873064
Drug: everolimus (trough
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus (trough levels 3-8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL)
Study: 25873064
Drug: standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard tacrolimus (trough levels 6-10 ng/mL)
Study: 10409125
Drug: DCA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCA (100 mg/kg body mass)
Study: 24384646
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen-based hormone therapy (HT)
Study: 22648840
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding with enteral nutrition preparation
Study: 20395537
Drug: Darifenacin ER
Normalized name: Darifenacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin ER 7.5 mg
Study: 20395537
Drug: Darifenacin ER
Normalized name: Darifenacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin ER 15 mg
Study: 20140437
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg
Study: 18713926
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/kg followed by 83 microg x kg(‐1) x h(‐1) (ketamine-2 group)
Study: 12391068
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg twice daily for 5 doses)
Study: 1642024
Drug: Piroxicam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (0.3 mg/kg)
Study: 21959480
Drug: Diclofenac (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (1 mg/kg)
Study: 12161042
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isoflavones (Promensil)
Study: 10519337
Drug: Lignocaine-prilocaine cream
Normalized name: lidocaine / prilocaine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine-prilocaine cream (EMLA)
Study: 8443031
Drug: Digoxin tablets
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin tablets (250 micrograms)
Study: 8443031
Drug: Liquid filled
Normalized name: Senna Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid filled digoxin capsules (100 micrograms)
Study: 8443031
Drug: Experimental enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental enteric-coated capsule (100 micrograms)
Study: 6766049
Drug: Intravenous control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous control
Study: 2428462
Drug: Alternating regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating regimen (same drugs alternating in monthly cycles with doxorubicin, dacarbazine, and bleomycin)
Study: 23318149
Drug: Intranasal H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal H1N1 vaccine
Study: 2895483
Drug: Remoxipride 150‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 150‐600 mg/day
Study: 25539805
Drug: Alternative-mechanism TNF-inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative-mechanism TNF-inhibitor (TNFi) or abatacept
Study: 18707799
Drug: Topical methyl-aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl-aminolevulinate (MAL) cream applied under occlusion for 3 hours, followed by illumination with red light-emitting diode (630 nm, light dose 37 J/cm2)
Study: 18707799
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied under occlusion for 3 hours, followed by illumination with red light-emitting diode (630 nm, light dose 37 J/cm2)
Study: 2717521
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral ketorolac tromethamine (KT)
Study: 2717521
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intramuscular ketorolac tromethamine (KT)
Study: 25933031
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly
Study: 19075192
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Alendronate and Indapamide
Study: 15179024
Drug: Acamprosate 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 2000 mg/day
Study: 11216976
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral loading dose of propafenone (600 mg)
Study: 2271372
Drug: Cholestyramine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (8 g)
Study: 510196
Drug: 10 tablets
Normalized name: ALLANTOIN 0.11 in 600 mg VAGINAL TABLET [Jilgyungyi (10 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 tablets of 800 mg bacampicillin (t.i.d.)
Study: 510196
Drug: 20 tablets
Normalized name: ALLANTOIN 0.11 in 600 mg VAGINAL TABLET [Jilgyungyi (20 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 tablets of 800 mg bacampicillin (t.i.d.)
Study: 510196
Drug: 30 tablets
Normalized name: nitrogen 30 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 tablets of 800 mg bacampicillin (t.i.d.)
Study: 16033749
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline
Study: 16033749
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin for the surgical patient
Study: 16033749
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin for the surgical patient and all household members
Study: 28007331
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (rosuvastatin 5 mg/ezetimibe 10 mg, rosuvastatin 10 mg/ezetimibe 10 mg, rosuvastatin 20 mg/ezetimibe 10 mg)
Study: 28007331
Drug: Monotherapy (rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (rosuvastatin 5 mg, rosuvastatin 10 mg, rosuvastatin 20 mg)
Study: 25997043
Drug: Purified anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified anthocyanin (320 mg/d)
Study: 19802534
Drug: Shenshao Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenshao Tablet (SST)
Study: 15297779
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg once daily in the morning
Study: 9258989
Drug: Cotinine fumarate
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine fumarate (40, 80, or 160 mg)
Study: 23312808
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment only
Study: 28703421
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) with supportive treatment
Study: 22327873
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin
Study: 9699761
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin
Study: 22699036
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg nitroglycerin
Study: 22699036
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nitroglycerin
Study: 22699036
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lidocaine + 30 mg nitroglycerin
Study: 22699036
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lidocaine + 30 mg nitroglycerin
Study: 19320851
Drug: Ciclesonide (CIC)
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide (CIC) 320 μg
Study: 18339441
Drug: Achievers (maintained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achievers (maintained glucose levels below 8mmol/L)
Study: 8562293
Drug: Litoxetine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litoxetine (twice daily for 4 days)
Study: 6988006
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid treatment (betamethasone)
Study: 31823552
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (Group B)
Study: 31823552
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy combined with autologous PRP injection (Group C)
Study: 20003205
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (Hyalubrix) injections
Study: 12875478
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg o.d.
Study: 3319646
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg o.d.
Study: 12875478
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Lacidipine and Chlorthalidone)
Study: 10383520
Drug: LTdbCA (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTdbCA (lansoprazole 30 mg b.d., tri-potassium dicitrato bismuthate one tablet b.d., clarithromycin 250 mg b.d., amoxycillin 1 g b.d. for 3 days)
Study: 10383520
Drug: RbcCA (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RbcCA (ranitidine bismuth citrate 400 mg b.d., clarithromycin 250 mg b.d., amoxycillin 1 g b.d. for 3 days)
Study: 10383520
Drug: OCM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. for 1 week)
Study: 6342133
Drug: Debrisoquin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquin (20 mg/day)
Study: 6342133
Drug: Methyldopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (100 mg/day)
Study: 2481787
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg/day)
Study: 30497202
Drug: Classic surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic surgical and rehabilitative treatments
Study: 12084664
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO(2)
Study: 31437853
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air inhalation
Study: 9708611
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (1 g administered orally before and after hemodialysis treatments)
Study: 7609274
Drug: No-Iron (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Iron (total parenteral nutrition without iron)
Study: 2227819
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg/day) for 5 weeks
Study: 660211
Drug: Once or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice a day dosage regimens of phenytoin
Study: 30942029
Drug: Auricular gold-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular gold-needle therapy
Study: 6562990
Drug: Intravaginal application
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal application of oestriol tablets (1 to 3 mg daily for 1 or more cycles)
Study: 31500690
Drug: Maintenance supplements
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance supplements of 1,000 IU/day for those with normal serum 25(OH)D levels
Study: 3140587
Drug: Bromocriptine 5
Normalized name: bromocriptine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 5 mg daily for 4 cycles
Study: 31915235
Drug: VA-dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-dual therapy
Study: 31915235
Drug: VAC-triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-triple therapy
Study: 29426008
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice-daily)
Study: 16800099
Drug: Topical nimesulide
Normalized name: nimesulide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nimesulide gel (Sulidin gel 1%)
Study: 23688323
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg)
Study: 24295556
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg once-daily (OD)
Study: 24295556
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg OD
Study: 12608492
Drug: Naltrexone 100
Normalized name: naltrexone 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 100 mg/day
Study: 18384246
Drug: Naltrexone 150
Normalized name: METHYLNALTREXONE 150MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 150 mg/day
Study: 10960002
Drug: Acetabular augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetabular augmentation screws or offset acetabular liners
Study: 9303395
Drug: Ceftriaxone and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone and/or cefuroxime axetil (1 to 2 g once to twice daily and 500 mg twice daily respectively)
Study: 8347269
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg p.o.) administered 6 hours prior to transplant surgery
Study: 22944906
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion
Study: 3010693
Drug: Atenolol (beta‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta‐adrenoceptor antagonist)
Study: 2574496
Drug: Timolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (non-selective beta blocker)
Study: 113217
Drug: Propranolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (non-selective beta blocker)
Study: 30219705
Drug: Theophylline 250
Normalized name: theophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 250 mg
Study: 22805388
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) therapy, administered three-times weekly for one year
Study: 22805388
Drug: No rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rhGH therapy (year before treatment)
Study: 10351970
Drug: Digoxin (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (serum concentration, 1.29+/‐0.35 nmol/L)
Study: 2008268
Drug: Xenon photocoagulation
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon photocoagulation treatment
Study: 28730694
Drug: RG7697 (0.25-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7697 (0.25-2.5 mg)
Study: 28730694
Drug: RG7697 (≥0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7697 (≥0.75 mg)
Study: 28730694
Drug: RG7697 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7697 (2.5 mg)
Study: 28730694
Drug: RG7697 (≥1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7697 (≥1.1 mg)
Study: 3929301
Drug: d-amphetamine (AMP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMP; 10 mg)
Study: 3929301
Drug: d-amphetamine (AMP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMP; 2.5 mg)
Study: 8799523
Drug: diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (10 mg)
Study: 24666210
Drug: Spirometry testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirometry testing before and after bronchodilator (BD) using the EasyOne spirometer.
Study: 22686204
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg daily for 1 year)
Study: 23140261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no metformin)
Study: 18062520
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg followed by pethidine 20 mg intravenously
Study: 12666828
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg selenite daily, increased fish intake (at least three fish dinners weekly)
Study: 12666828
Drug: Placebo tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, increased fish intake (at least three fish dinners weekly)
Study: 12666828
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg Se-methionine daily, increased fish intake (at least three fish dinners weekly)
Study: 12666828
Drug: No selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: No selenium supplementation, increased fish intake (at least three fish dinners weekly)
Study: 2478793
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg t.i.d.)
Study: 8761775
Drug: 0.1 p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 p. 100 adapalene gel
Study: 8761775
Drug: 0.03 p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 p. 100 adapalene gel
Study: 8761775
Drug: 0.025 p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 p. 100 tretinoin gel
Study: 6118121
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol for 3 days
Study: 19442491
Drug: Immediate discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate discontinuation of current antipsychotic with aripiprazole (10 mg)